Role of SLURP-1 in Melanoma and Melanoma Stem Cells

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2011 by National Taiwan University Hospital
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01281722
First received: January 20, 2011
Last updated: January 21, 2011
Last verified: January 2011
  Purpose

Melanoma is the most aggressive skin cancer, with a propensity to metastasize, and is resistant to most of the current therapeutic regimens. Incidence rate of melanoma in patients with MDM (Mal De Maleda, with SLURP-1 mutation) is much higher than normal counterpart. SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1) is an allosteric agonist to the nicotinic acetylcholine receptor (nAchR) and it regulates epidermal homeostasis and T-cell function. The preliminary results of comparing human peripheral blood mononuclear cells (PBMCs) from 4 affected and 15 unaffected members from the family with MDM revealed that T-cell activation was impaired in PBMCs with the heterozygous and homozygous SLURP-1 G86R mutation. (2 of affected members developed melanoma.) Since there is currently no effective treatment for metastatic melanoma, identifying novel molecular mechanisms may lead to development of new treatments for metastatic melanomas.

Previous study showed that melanoma stem cells (MSCs) are crucial in melanoma pathogenesis: 1.Melanoma contains ABCB5, CD133 and ABCG2 positive cells had enhanced tumorigenic potential. 2.Higher frequencies of cells capable of initiating melanoma xenografts when using IL2Rγ-/- NOD SCID mice. These data confirmed the interaction between T cells and MSCs.

In this project, we will investigate the roles of SLURP-1 in melanoma and MSCs. Investigating and verifying the interaction between T-cells from patients with MDM and melanoma cells to confirm the SLURP-1 function of tumorigenesis in xenotransplant mice (IL2Rγ-/- NOD SCID) model. To reveal the role of SLURP-1 silencing in melanoma cell lines by using not only A2058 , A375 and MeWo mwlanima cell lines but also ABCB5+ melanoma cells and ABCB5- melanoma cells through the tumorigenesis, apoptosis,angiogenesis, proliferation, melanosphere formation assays.

The aim of this project is to investigate the roles and molecular mechanisms of SLURP-1 in melanoma carcinogenesis, which may improve the development of novel treatments for melanoma.


Condition
Melanoma;

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples With DNA

serum, DNA, tissue


Estimated Enrollment: 150
Study Start Date: January 2011
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
healthy adults
healthy adults with the age among 20 to 95 years old
melanoma cases
the people who are diagnosed melanoma in NTU hospital

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

case and control study of melanoma disease

Criteria

Inclusion Criteria:

  • Clinical diagnosis of melanoma Disease by NTU hospital(group of cases)
  • healthy adults(groups of control)

Exclusion Criteria:

  • two groups whose age are younger than 20 or older tha 95 years old
  • Clinical diagnosis of non-melanoma Disease by NTU hospital(group of cases)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01281722

Contacts
Contact: Shiou-Hwa Jee, M.D., Ph.D. 886-9-72651116 shiouhwa@gmail.com; shiouhwa@ntu.edu.tw

Locations
Taiwan
Department of Dermatology, National Taiwan University Hospital. Recruiting
Taipei, Taiwan, 100
Contact: Shiou-Hwa Jee, M.D., Ph.D.    886-9-72651116    shiouhwa@gmail.com; shiouhwa@ntu.edu.tw   
Sub-Investigator: Jung-Ting Kao, M.D.         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Shiou-Hwa Jee, M.D., Ph.D. Department of Dermatology, National Taiwan University Hospital.
  More Information

No publications provided

Responsible Party: Shiou-Hwa Jee, M.D., Ph.D., Professor,Department of Dermatology,National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01281722     History of Changes
Other Study ID Numbers: 201012044RB
Study First Received: January 20, 2011
Last Updated: January 21, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
healthy adults
melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on August 28, 2014